17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers

Patient Education, Device Counselling, Health Literacy & Overcoming Barriers

Patient education and counselling constitute a core clinical standard of Canadian pharmacy practice. Pharmacists possess an ethical and legal fiduciary obligation to ensure that patients comprehend their medication regimens, understand expected therapeutic outcomes, recognize significant adverse effects, and demonstrate flawless technical proficiency with complex drug delivery devices. Clear, structured patient communication directly mitigates medication misadventures, improves health literacy, and fosters durable therapeutic partnerships.

---

Structuring Patient Consultations: Proven Communication Frameworks

To conduct focused, efficient, and interactive clinical consultations that avoid one-way lecturing, Canadian pharmacists utilize two validated interactive frameworks: the Three Prime Questions for new medications and the Show-and-Tell Technique for refills.

The Three Prime Questions (Indian Health Service Model)

Originally developed by the United States Indian Health Service (IHS) and adopted widely across Canadian pharmacy curricula and licensing examinations, this open-ended framework establishes the patient's baseline knowledge and allows the pharmacist to fill in gaps and correct misconceptions:

                        THE THREE PRIME QUESTIONS MODEL

   PRIME QUESTION 1: "What did your doctor tell you this medication is for?"
   ┌────────────────────────────────────────────────────────────────────────┐
   │ • Assesses understanding of the diagnosis and therapeutic purpose.     │
   │ • Identifies the patient's personal goals and expectations.            │
   └────────────────────────────────────────────────────────────────────────┘
                                       │
                                       ▼
   PRIME QUESTION 2: "How did your doctor tell you to take it?"
   ┌────────────────────────────────────────────────────────────────────────┐
   │ • Assesses dosage, frequency, administration timing, and route.        │
   │ • Clarifies relationship to meals (with/without food) and duration.    │
   │ • Probes missed-dose protocols and storage parameters.                 │
   └────────────────────────────────────────────────────────────────────────┘
                                       │
                                       ▼
   PRIME QUESTION 3: "What did your doctor tell you to expect?"
   ┌────────────────────────────────────────────────────────────────────────┐
   │ • Assesses expected therapeutic timeline (when benefit begins).        │
   │ • Discusses common manageable side effects vs. serious red flags.      │
   │ • Outlines what steps to take if adverse reactions occur.              │
   └────────────────────────────────────────────────────────────────────────┘

• Closing the New Consultation: The pharmacist concludes by confirming comprehension via teach-back: "Just to make sure we covered everything clearly today, how are you going to take this medication when you get home?"

The "Show-and-Tell" Technique for Refill Consultations

When patients return for medication refills, pharmacists must not assume continued proper usage or ongoing tolerability. The Show-and-Tell approach is an interactive, visual verification technique:

1. Display the Medication: The pharmacist opens the vial or shows the package to the patient, displaying the tablets or device.
2. Engage with Core Open-Ended Questions:
   • "What do you take this medication for?" (Verifies ongoing understanding of indication);
   • "How are you currently taking this medication?" (Uncovers actual daily adherence patterns, skipped doses, or unauthorized self-titration);
   • "What problems or changes have you noticed since you started taking it?" (Screens for late-emerging adverse effects, lack of therapeutic efficacy, or new drug interactions).
3. Refill Adherence Assessment: The pharmacist cross-references the patient's refill interval against the dispensed days supply. A 30-day supply refilled every 45 days reveals a significant non-adherence rate of ~33%, requiring root-cause exploration.

---

Health Literacy & Plain-Language Communication

Health literacy refers to an individual's ability to access, comprehend, evaluate, and communicate health information in order to make informed health decisions. According to national Canadian surveys, approximately 60% of Canadian adults and 88% of seniors possess low health literacy, placing them at heightened risk for medication dosing errors, hospital readmissions, and elevated mortality.

Red Flags of Low Health Literacy in Pharmacy Practice

• Incomplete patient intake or health history questionnaires;
• Stating, "I forgot my reading glasses; I'll read this pamphlet when I get home";
• Identifying medications exclusively by the color, shape, or imprint of the pill rather than by drug name or strength;
• Inability to articulate the clinical purpose of chronic medications;
• Missing routine laboratory monitoring appointments or showing poor follow-through on therapeutic plans.

Plain-Language Communication Principles

To bridge health literacy disparities, pharmacists must translate complex medical terminology into plain, everyday language and adhere to strict readability standards:

• Target Reading Level: Written patient education materials (leaflets, action plans, auxiliary labels) must be composed at a 5th-to-8th grade reading level (assessed via Flesch-Kincaid or SMOG readability formulas).
• Avoiding Medical Jargon:

The Teach-Back Method & "Chunk and Check"

The Teach-Back method is an evidence-based communication verification standard endorsed by the Canadian Patient Safety Institute. It evaluates the clarity of the clinician's communication—not the intelligence of the patient.

• Effective Phrasing: "I want to make sure I gave you clear information today. When you explain this to your partner tonight, what will you tell them about how to use this inhaler?"
• Chunk and Check: Complex information is broken down into small, distinct "chunks." The pharmacist explains one concept (e.g., priming the device), verifies comprehension via teach-back, and only then proceeds to the next concept (e.g., inhalation technique).

---

Specialized Device Counselling Protocols

Incorrect device technique is exceptionally prevalent in clinical practice, resulting in therapeutic failure and disease exacerbations. Pharmacists must demonstrate physical mastery of each device and execute structured, hands-on patient education.

1. Inhaler Delivery Systems

                      RESPIRATORY INHALER COMPARISON MATRIX

  DEVICE CLASS            MECHANISM                INHALATION VELOCITY        KEY CLINICAL PEARLS
┌─────────────────┬──────────────────────┬───────────────────────────────┬──────────────────────────────┐
│ pMDI with       │ Propellant aerosol   │ SLOW & DEEP                   │ • Shake 3–5 seconds.         │
│ Spacer / Chamber│ generated by canister│ (over 3 to 5 seconds;         │ • Wait 30–60s between puffs. │
│                 │ depression.          │ whistling = inhaling too fast)│ • Rinse & spit for ICS.      │
├─────────────────┼──────────────────────┼───────────────────────────────┼──────────────────────────────┤
│ Dry Powder      │ Breath-actuated;     │ RAPID, FORCEFUL & DEEP        │ • NEVER exhale into device.  │
│ Inhalers (DPI)  │ patient's inspiratory│ (from the very start of the   │ • Keep Turbuhaler upright    │
│ (Turbuhaler /   │ flow disperses micron│ breath to disaggregate the    │   when loading dose.         │
│  Diskus)        │ drug particles.      │ powder).                      │ • Rinse & spit for ICS.      │
├─────────────────┼──────────────────────┼───────────────────────────────┼──────────────────────────────┤
│ Soft Mist       │ Mechanical spring    │ SLOW & DEEP                   │ • TOP mnemonic (Turn,        │
│ Inhaler (SMI)   │ forces liquid through│ (over 4 to 5 seconds; long-   │   Open, Press).              │
│ (Respimat)      │ fine uniblock nozzle.│ lasting low-velocity mist).   │ • High lung deposition.      │
└─────────────────┴──────────────────────┴───────────────────────────────┴──────────────────────────────┘

Pressurized Metered-Dose Inhaler (pMDI) with Valved Holding Chamber (Spacer):

1. Preparation: Remove protective caps from both MDI and spacer. Inspect for foreign debris. Shake the pMDI vigorously for 3 to 5 seconds. Prime the canister if it is new or has been unused for > 7–14 days.
2. Assembly & Posture: Insert the MDI canister into the rubber adapter of the spacer. Instruct the patient to sit or stand upright to maximize lung volume.
3. Exhalation: Exhale gently and completely away from the spacer mouthpiece.
4. Placement: Place spacer mouthpiece between teeth and seal lips firmly around it. Keep tongue flat.
5. Actuation & Inhalation: Depress the canister ONCE to release a single dose into the chamber. Inhale slowly and deeply over 3 to 5 seconds. If the spacer produces a high-pitched whistling sound, the patient is inhaling too rapidly.
6. Breath-Hold: Remove mouthpiece from mouth and hold breath for up to 10 seconds (or as long as comfortable), then breathe out gently.
7. Multiple Puffs: If a second puff is prescribed, wait 30 to 60 seconds before repeating the steps (vital for beta-2 agonists like salbutamol to allow the first dose to open airways and ensure propellant pressure recovery).
8. Post-Administration Hygiene: If the inhaler contains an Inhaled Corticosteroid (ICS) (e.g., fluticasone, budesonide, beclomethasone), rinse mouth thoroughly with water and spit it out to prevent local adverse effects: oropharyngeal candidiasis (thrush) and dysphonia (hoarseness).
9. Spacer Cleaning Protocol: Disassemble and wash weekly in warm water with mild liquid dish detergent. Do not scrub or rub dry with a cloth (which generates electrostatic charges that trap aerosol particles on the plastic walls); allow to air dry completely.

Dry Powder Inhalers (DPIs):

• Turbuhaler Technique:
  1. Unscrew and remove the white protective cover.
  2. Hold the device strictly upright (vertical) while loading the dose. Twist the colored grip at the base fully in one direction, and then twist it back until a distinct "click" is heard.
  3. Breathe out completely away from the inhaler (never breathe into the Turbuhaler; exhaled moisture clumps the dry powder).
  4. Place mouthpiece between lips, sealing tightly. Inhale rapidly, forcefully, and deeply.
  5. Hold breath for up to 10 seconds, then breathe out away from the unit. Rinse and spit if ICS.
• Diskus Technique:
  1. Hold outer case in one hand; place thumb of other hand on thumb-grip and push away until mouthpiece appears.
  2. Slide the lever horizontally away from the mouthpiece until a click is heard (punctures/advances blister).
  3. Exhale away from device. Inhale steadily, forcefully, and deeply through the mouthpiece. Hold breath for 10 seconds. Close device. Rinse and spit if ICS.

Soft Mist Inhaler (Respimat):

• Utilize the TOP mnemonic:
  • T (Turn): Keep cap closed. Turn the clear plastic base in the direction of the red arrows until it clicks (one-half turn).
  • O (Open): Flip the protective cap fully open until it snaps into place.
  • P (Press): Exhale away from device. Close lips around mouthpiece without covering air vents. Point inhaler toward back of throat, press the dose-release button, and breathe in slowly and deeply over 4 to 5 seconds. Hold breath up to 10 seconds.

---

2. Subcutaneous Insulin Pens

                      INSULIN PEN ADMINISTRATION PROTOCOL

  1. CHECK & MIX      Inspect clarity. If cloudy (NPH/premix), gently invert/roll 10 times.
  2. ATTACH NEEDLE    Disinfect rubber seal; screw new pen needle straight on.
  3. SAFETY PRIME     Dial 2 units; point upright; press button until insulin droplet appears.
  4. DIAL DOSE        Dial the exact prescribed dose on the dosage window.
  5. INJECT AT 90°    Insert into skin at 90° (45° if lean); push button fully down.
  6. 5–10 SEC HOLD    Hold needle under skin for 5 to 10 SECONDS before withdrawal.
  7. DISPOSE NEEDLE   Remove needle immediately; discard in biohazard sharps container.

• Solution vs. Suspension: Rapid-acting (aspart, lispro, glulisine), short-acting (regular), and long-acting basal analogues (glargine, detemir, degludec) are clear solutions that require no mixing. Intermediate-acting (NPH) and premixed insulins are cloudy suspensions; they must be gently rolled between the palms and inverted 10 times until the suspension is uniformly milky white. Never shake vigorously (creates frothing and air bubbles).
• Safety Priming (Air Shot): Before every injection, dial 2 units, point needle upright, tap cartridge to dislodge air bubbles, and depress the push-button fully until a stream or drop of insulin emerges at the needle tip. This confirms needle patency and eliminates dead space air.
• Injection Technique: Select an anatomical site (abdomen >= 2 inches away from umbilicus, anterolateral thigh, or upper outer buttock). Cleanse skin. Insert needle at a 90-degree angle (a 45-degree angle may be used in very cachectic, emaciated individuals or young children to prevent accidental intramuscular injection). Depress push-button completely until the dose counter returns to zero.
• The Mandatory 5-to-10 Second Post-Injection Hold: The patient must maintain the needle fully embedded beneath the skin while holding the button down for at least 5 to 10 seconds before withdrawal. This dissipates tissue counter-pressure, prevents medication leakage from the puncture tract, and guarantees full dosage delivery.
• Needle Removal & Safety: Remove needle immediately after each injection and discard in an approved rigid biohazard sharps container. Leaving a needle attached allows air entry into the cartridge and medication leakage, altering concentration and accuracy.
• Site Rotation to Prevent Lipohypertrophy: Injections must be systematically rotated within anatomical areas, spacing consecutive punctures at least 1 cm (one finger-width) apart.

---

3. Blood Glucose Meters (BGM)

1. Hand Hygiene: Wash hands with warm water and soap; dry thoroughly. Warm water stimulates peripheral capillary vasodilation. Avoid using alcohol swabs if skin remains wet (residual alcohol dilutes blood, causes hemolysis, and creates inaccurate readings) and wash off fruit residues (which contain glucose that falsely spikes readings).
2. Lancing Technique: Prick the side/lateral edge of the fingertip, rather than the central pad. The lateral edges have lower nociceptor nerve density and greater vascular capillary loops, minimizing pain.
3. Blood Application: Touch the test strip to the blood drop via capillary action. Do not smear blood onto the strip.

---

4. Epinephrine Auto-Injectors (EpiPen)

Epinephrine is the absolute first-line, life-saving pharmacotherapy for acute anaphylaxis (involving airway compromise, wheezing, stridor, hypotension, generalized urticaria, angioedema, or severe crampy abdominal pain following allergen exposure).

                        EPIPEN ADMINISTRATION PROTOCOL

  1. GRASP IN FIST    Keep fingers and thumbs wrapped around middle of unit.
  2. BLUE TO SKY      Pull off the BLUE safety release cap straight up.
  3. ORANGE TO THIGH  Position orange needle tip near outer mid-thigh.
  4. PUSH & CLICK     Push firmly into outer thigh at 90° until a loud CLICK sounds.
  5. 3-SECOND HOLD    Hold firmly in place against thigh for 3 SECONDS.
  6. MASSAGE & 911    Remove device; massage site for 10 seconds; CALL 911 IMMEDIATELY.

• Counselling Mnemonic: "Blue to the sky, orange to the thigh."
• Operational Steps:
  1. Form a fist around the center of the auto-injector. Never place thumb or fingers over either end (prevents accidental digital discharge and severe local ischemic necrosis from alpha-1 vasoconstriction).
  2. Pull the blue safety cap straight off with the other hand.
  3. Hold the orange tip against the outer mid-thigh (vastus lateralis muscle). The injection can be delivered directly through clothing if necessary.
  4. Push the orange tip firmly into the thigh at a 90-degree angle until a loud click is heard.
  5. Hold firmly in place against the thigh for 3 seconds (historically 10 seconds; modernized manufacturer protocol is 3 seconds).
  6. Remove pen from thigh (the orange needle cover automatically extends to conceal the needle). Massage the injection area for 10 seconds to accelerate systemic absorption.
• Mandatory Emergency Action: Immediately call 911 or seek emergency medical transport. Anaphylaxis carries a severe risk of a biphasic reaction—a life-threatening recurrence of respiratory failure or cardiovascular collapse occurring hours (typically 8–10 hours) after apparent initial recovery. If symptoms do not improve or worsen after 5 to 15 minutes, a second epinephrine auto-injector must be administered from a new unit.

---

Overcoming Adherence Barriers: Intentional vs. Unintentional Non-Adherence

Non-adherence accounts for substantial morbidity and unnecessary Canadian healthcare expenditure. Effective intervention requires differentiating between intentional and unintentional drivers:

                       ADHERENCE BARRIER STRATIFICATION

                 INTENTIONAL NON-ADHERENCE                   UNINTENTIONAL NON-ADHERENCE
    ┌──────────────────────────────────────────┐  ┌──────────────────────────────────────────┐
    │ • Root Causes:                           │  │ • Root Causes:                           │
    │   - Health beliefs & skepticism          │  │   - Forgetfulness & cognitive impairment │
    │   - Fear of side effects or dependence   │  │   - Complex multi-drug dosing schedules  │
    │   - Financial toxicity (drug costs)      │  │   - Physical dexterity & vision deficits │
    │   - Perceived lack of clinical efficacy  │  │   - Misunderstanding of instructions     │
    ├──────────────────────────────────────────┤  ├──────────────────────────────────────────┤
    │ • Clinical Solutions:                    │  │ • Clinical Solutions:                    │
    │   - Motivational Interviewing            │  │   - Multi-dose compliance packaging      │
    │   - Shared decision-making               │  │   - Simplified once-daily regimens       │
    │   - Deprescribing unneeded agents        │  │   - Fixed-dose combination tablets       │
    │   - Switching to low-cost formulary      │  │   - Non-child-resistant closures         │
    │     generics / provincial copay support  │  │   - Smartphone alarm reminders           │
    └──────────────────────────────────────────┘  └──────────────────────────────────────────┘

Clinical Implementation of Adherence Tools:

1. Compliance Packaging (Blister Packs / Dosette Boxes): Multi-dose blister packaging organizes oral solid dosage forms by day of the week and administration time (breakfast, lunch, dinner, bedtime). It provides immediate visual confirmation of whether a dose was taken, substantially resolving unintentional forgetfulness.
2. Regimen Simplification: Switching from multiple daily doses to once-daily extended-release formulations (e.g., converting metformin immediate-release 500 mg TID to metformin XR 1,500 mg once daily) or adopting Fixed-Dose Combinations (FDCs) (e.g., combining an ACEi and CCB into a single capsule, such as perindopril/amlodipine).
3. Overcoming Physical Disabilities: For patients with severe rheumatoid arthritis, Parkinsonian tremors, or stroke hemiparesis, pharmacists can authorize easy-open non-child-resistant caps (requiring documented patient consent), provide commercial bottle-opening grips, or supply eye-drop compliance aids.

---

Clinical Case Scenario: Inhaler Technique Assessment and Adherence Optimization

A 58-year-old female with moderate chronic obstructive pulmonary disease (COPD) presents for a refill of her budesonide/formoterol Turbuhaler (200/6 mcg, 2 puffs BID) and salbutamol pMDI (100 mcg, 1–2 puffs Q4H PRN). Dispensing records show she has refilled her budesonide/formoterol only twice in the past 6 months (indicating < 35% adherence), while refilling her salbutamol rescue inhaler every 3 weeks. She reports worsening exertional dyspnea, daily morning coughing, and frequent oral discomfort.

Step-by-Step Clinical Pharmacist Intervention:

1. Physical Examination of Oral Cavity: Inspection of the patient's mouth reveals creamy white curd-like plaques on the buccal mucosa and tongue that scrape off leaving an erythematous base—diagnostic of oropharyngeal candidiasis (oral thrush) secondary to inhaled corticosteroid deposition.
2. Device Demonstration & Root-Cause Analysis: The pharmacist asks the patient to demonstrate how she uses her Turbuhaler using a placebo trainer. Two critical errors are observed:
   • She holds the Turbuhaler horizontally while twisting the base back and forth;
   • She exhales deeply directly into the mouthpiece before taking a slow, weak breath.
3. Patient Interviewing & Belief Exploration: Using open-ended questions, the pharmacist discovers that the patient stopped taking the Turbuhaler regularly because her mouth became painful (the thrush) and she believed the Turbuhaler "wasn't working because I never feel anything entering my lungs, whereas the blue spray works immediately."
4. Structured Corrective Action Plan:
   • Treating the Adverse Effect: The pharmacist collaborates with the primary care physician to prescribe Nystatin oral suspension 100,000 units/mL, 5 mL swish and swallow QID for 14 days.
   • Device Education (Turbuhaler): The pharmacist instructs the patient to keep the Turbuhaler strictly upright when twisting the colored grip until it clicks; to exhale completely away from the inhaler; to inhale rapidly, forcefully, and deeply; and to rinse her mouth with water and spit it out after every morning and evening dose.
   • Explaining Controller vs. Reliever Physiology: The pharmacist explains that budesonide is a "preventer" (controller) that reduces underlying chronic airway swelling over weeks and has no taste or sensation, whereas salbutamol is a "reliever" that only opens airways temporarily without treating the root disease.
   • Adding a Spacer to the Rescue Inhaler: The pharmacist provides and educates the patient on an AeroChamber spacer for her salbutamol pMDI to optimize lung delivery during acute dyspnea.